Immunonkologie beim triple-negativen Mammakarzinom

Die Rolle des Immunsystems beim Mammakarzinom rückt zunehmend in den Fokus immunonkologischer Forschungsprojekte. Insbesondere das triple-negative Mammakarzinom (TNBC) verfügt im Vergleich zu den anderen Tumorsubtypen über ein ausgeprägtes immunogenes Potenzial. Möglichkeiten einer immunonkologischen Therapie ergeben sich durch Immuncheckpoint-Inhibition, Vakzinierung oder adoptiven T-Zell-Transfer.

Kernaussagen

• TILs haben prognostische und prädiktive Bedeutung beim triple-negativen Mammakarzinom.

• Der Krebs-Immunzell-Zyklus bietet verschiedene therapeutische Angriffspunkte zur Entwicklung und Etablierung personalisierter Immuntherapien.

• Immuncheckpoint-Inhibitoren (insbesondere Atezolizumab) sind in Kombination mit Chemotherapie eine wirksame Therapieoption beim metastasierten triple-negativen Mammakarzinom, aktuell existiert in Deutschland jedoch noch keine Zulassung.

• Vakzinierung und adoptiver T-Zell-Transfer sind weitere vielversprechende immuntherapeutische Ansätze.

Schlüsselwörter

Immuncheckpoint-Inhibitoren - Vakzinierung - TIL - tumorinfiltrierende Lymphozyten - PD-1 - PD-L1 - Krebs-Immunzell-Zyklus

• Literatur

• 1 Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015; 348: 69-74
• 2 Denkert C, Minckwitz G von Darb-Esfahani S. et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 2018; 19: 40-50
• 3 Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39: 1-10 doi:10.1016/j.immuni.2013.07.012
• 4 Metzger-Filho O, Tutt A, de Azambuja E. et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 2012; 30: 1879-1887
• 5 Schmidt M, Böhm D, von Törne C. et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008; 68: 5405-5413
• 6 Salgado R, Denkert C, Demaria S. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2015; 26: 259-271
• 7 Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015; 33: 1974-1982
• 8 Nanda R, Chow LQ, Dees EC. et al. Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 Study. J Clin Oncol 2016; 34: 2460-2467
• 9 Dirix LY, Takacs I, Jerusalem G. et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat 2018; 167: 671-686
• 10 Emens LA, Cruz C, Braiteh FS. et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer. JAMA Oncol 2018; 5: 74-82 doi:10.1001/jamaoncol.2018.4224
• 11 Adams S, Diamond JR, Hamilton E. et al. Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: A phase 1b clinical trial. JAMA Oncol 2018; DOI: 10.1001/jamaoncol.2018.5152.
• 12 Schmid P, Adams S, Rugo HS. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018; 379: 2108-2121 doi:10.1056/NEJMoa1809615
• 13 Brahmer JR, Lacchetti C, Schneider BJ. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36: 1714-1768 doi:10.1200/JCO.2017.77.6385
• 14 Wolchok JD, Hoos A, OʼDay S. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-7420
• 15 Zacharakis N, Chinnasamy H, Black M. et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med 2018; 24: 724-730 doi:10.1038/s41591-018-0040-8
• 16 Peoples GE, Gurney JM, Hueman MT. et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 2005; 23: 7536-7545 doi:10.1200/JCO.2005.03.047
• 17 Tureci O, Vormehr M, Diken M. et al. Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines. Clin Cancer Res 2016; 22: 1885-1896 doi:10.1158/1078-0432.CCR-15-1509
• 18 Kreiter S, Vormehr M, van de Roemer N. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 2015; 520: 692-696 doi:10.1038/nature14426
• 19 Sahin U, Derhovanessian E, Miller M. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 2017; 547: 222-226 doi:10.1038/nature23003
• 20 Schmidt M, Bolte S, Frenzel K. et al. Highly innovative personalized RNA-immunotherapy for patients with triple negative breast cancer. SABCS 2018; DOI: 10.1158/1538-7445.SABCS18-OT2-06-01. Stand: February 2019